Mounjaro 12.5mg contains Tirzepatide, an advanced dual-action GIP and GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes. It works by enhancing insulin release, reducing glucose production in the liver, and slowing digestion to support weight management.
This strength (12.5mg) is usually prescribed after the patient has tolerated and responded well to lower doses (2.5mg, 5mg, 7.5mg, 10mg).
---
Uses:
Improves blood sugar levels in type 2 diabetes patients
May aid in weight management under medical supervision
Lowers HbA1c (long-term blood sugar levels)
Helps reduce risk of diabetes-related complications
---
Dosage & Administration:
Usual dose: 12.5mg once weekly as a subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm.
Administered on the same day each week.
Dosage adjustments should be made only by a healthcare provider.
Rotate injection sites to avoid irritation.
---
Side Effects:
Common:
Nausea, vomiting, diarrhea
Constipation
Loss of appetite
Abdominal discomfort
Serious but less common:
Pancreatitis (severe abdominal pain)
Gallbladder issues
Allergic reactions (rash, swelling, difficulty breathing)
Thyroid tumors (seen in animal studies)
👉 Contact a healthcare provider immediately if severe or unusual symptoms occur.
---
Precautions:
Not for people with type 1 diabetes or diabetic ketoacidosis
Avoid if you or your family have a history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome
Use cautiously if you have kidney, pancreas, or gastrointestinal problems
Not recommended during pregnancy or breastfeeding unless prescribed
---
Storage:
Keep refrigerated at 2°C – 8°C.
Do not freeze.
Protect from light and heat.
